Overview

* Sagimet reports Q3 net loss of $12.9 mln

* R&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024

* Cash and equivalents stand at $125.5 mln as of September 30, 2025

Outlook

* Sagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026

* Company plans Phase 2 trial for denifanstat and resmetirom pending regulatory consultation

* Sagimet expects Phase 2 acne trial in 2026 following TVB-3567 Phase 1 trial

Result Drivers

* CLINICAL TRIALS - Initiated Phase 1 PK trial for denifanstat and resmetirom combination, targeting MASH with F4 fibrosis

* ACNE DEVELOPMENT - Ongoing Phase 1 trial of TVB-3567 for acne indication

* COSTS DROP - R&R and G&A expenses decline, helping overall results

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$12.91

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Sagimet Biosciences Inc ( SGMT ) is $28.00, about 68.5% above its November 12 closing price of $8.82

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)